Please assess the completion status of the following clinical trial:

Trial Title: Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 6 years and older~* Subjects with CF as diagnosed by one of the following: documented sweat chloride \>= 60 mEq/L by quantitative pilocarpine iontophoresis test, or documented sweat sodium \>= 60 mmol/L, or 2 well characterized genetic mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, or abnormal nasal potential difference with accompanying symptoms characteristic of CF~* Documented PA in an expectorated sputum or throat swab culture within 3 months prior to Visit 1 or at Visit 1~* Subjects must be able to provide written informed consent/assent prior to any study related procedures; parent/guardian must be able to give written informed consent as necessary prior to any study related procedure~* Subjects must have received previous treatment with aerosolized antibiotics without demonstration of drug intolerance~* FEV1 \<= 75% predicted at Visit 1~* Ability to perform reproducible pulmonary function tests~* Chest radiograph at Visit 1 without significant acute findings (eg, infiltrates \[lobar or diffuse interstitial\], pleural effusion, pneumothorax); or chest radiograph or magnetic resonance image (MRI) obtained within the 180 days prior to Visit 1 without acute findings and no significant intercurrent illness; chronic, stable findings (eg, chronic scarring or atelectasis) are allowed~Exclusion Criteria:~* Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg prednisone a day or 20 mg prednisone every other day~* History of sputum or throat swab culture yielding B. cepacia in the previous 2 years~* Current requirement for daily continuous oxygen supplementation or requirement for more than 2 L/minute at night~* Administration of any investigational drug or device within 28 days of Visit 1 or within 6 half-lives of the investigational drug (whichever is longer)~* Known local or systemic hypersensitivity to monobactam antibiotics~* Known allergies/intolerance to tobramycin~* Inability to tolerate inhalation of a short acting beta agonist~* Changes in or initiation of chronic azithromycin treatment within 28 days prior to Visit 1~* Administration of antipseudomonal antibiotics by inhalation, intravenous or oral routes within the 14 days prior to Randomization/Visit 2~* Changes in antimicrobial, bronchodilator (BD), dornase alfa, or corticosteroid medications within 7 days prior to Visit 1~* Changes in physiotherapy technique or schedule within 7 days prior to Visit 1~* History of lung transplantation~* Abnormal renal or hepatic function or serum chemistry at Visit 1, defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT) \> 5 times upper limit of normal range (ULN) or creatinine \> 2 times ULN~* Positive pregnancy test at Visit 1; all women of childbearing potential will be tested~* Female of childbearing potential who is lactating or is not (in the opinion of the investigator) practicing an acceptable method of birth control; female subjects who utilize hormonal contraceptives as one of their birth control methods must have used the same method for at least 3 months before study dosing~* Any serious or active medical or psychiatric illness, which in the opinion of the investigator, would interfere with patient treatment, assessment, or compliance with the protocol

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZLI 75 mg 3 times a day (TID) (Type: EXPERIMENTAL): None
- TIS 300 mg 2 times a day (BID) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).